Dataset Information

Personalized statin treatment plan using counterfactual approach with multi-objective optimization over benefits and risks.

ABSTRACT:

Background

Statins are a class of drugs that lower cholesterol levels in the blood by inhibiting an enzyme called 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. High cholesterol levels can lead to plaque buildup in the arteries, which can cause Atherosclerotic Cardiovascular Disease(ASCVD). Statins can reduce the risk of ASCVD events by about 25-35% but they might be associated with symptoms such as muscle pain, liver damage, or diabetes. As a result, this leads to a strong reason to discontinue statin therapy, which increases the risk of cardiovascular events and mortality and becomes a public-health problem.To solve this problem, in the previous work, we proposed a framework to produce a proactive strategy, called a personalized statin treatment plan (PSTP) to minimize the risks of statin-associated symptoms and therapy discontinuation when prescribing statin. In our previous PSTP framework, three limitations remain, and they can influence PSTP usability: (1) Not taking the counterfactual predictions and confounding bias into account. (2) The balance between multiple drug-prescribing objectives (especially trade-off objectives), such as tradeoff between benefits and risks. (3) Evaluating PSTP in retrospective data.

Objectives

This manuscript aimed to provide solutions for the three abovementioned problems to improve PSTP robustness to produce a proactive strategy for statin prescription that can maximize the benefits (low-density lipoprotein cholesterol (LDL-C) reduction) and minimize risks (statin-associated symptoms and therapy discontinuation) at the same time.

Methods

We applied overlapping weighting counterfactual survival risk prediction (CP), multiple objective optimization (MOO), and clinical trial simulation (CTS) which consists of Random Arms, Clinical Guideline arms, PSTP Arms, and Practical Arms to improve the PSTP framework and usability.

Results

In addition to highly balanced covariates, in the CTS, the revised PSTP showed improvements in lowering the SAS risks overall compared to other arms across all time points by at most 7.5% to at least 1.0% (Fig. 8(a)). It also has the better flexibility of identifying the optimal Statin across all time points within one year.

Conclusion

We demonstrated feasibility of robust and trustworthy counterfactual survival risk prediction model. In CTS, we also demonstrated the PSTP with Pareto optimization can personalize optimal balance between Statin benefits and risks.

SUBMITTER: Liang Y

PROVIDER: S-EPMC10659576 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Personalized statin treatment plan using counterfactual approach with multi-objective optimization over benefits and risks.

Liang Yue Y Yew Pui Ying PY Loth Matt M Adam Terrence J TJ Wolfson Julian J Tonellato Peter J PJ Chi Chin-Lin CL

Informatics in medicine unlocked 20231002

<h4>Background</h4>Statins are a class of drugs that lower cholesterol levels in the blood by inhibiting an enzyme called 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. High cholesterol levels can lead to plaque buildup in the arteries, which can cause Atherosclerotic Cardiovascular Disease(ASCVD). Statins can reduce the risk of ASCVD events by about 25-35% but they might be associated with symptoms such as muscle pain, liver damage, or diabetes. As a result, this leads to a strong ...[more]

PMID: 37986733

Similar Datasets

Project description:In scientific disciplines, benchmarks play a vital role in driving progress forward. For a benchmark to be effective, it must closely resemble real-world tasks. If the level of difficulty or relevance is inadequate, it can impede progress in the field. Moreover, benchmarks should have low computational overhead to ensure accessibility and repeatability. The objective is to achieve a kind of ``Turing test'' by creating a surrogate model that is practically indistinguishable from the ground truth observation, at least within the dataset's explored boundaries. This objective necessitates a large quantity of data. This data encompasses numerous features that are characteristic of chemistry and materials science optimization tasks that are relevant to industry. These features include high levels of noise, multiple fidelities, multiple objectives, linear constraints, non-linear correlations, and failure regions. We performed 494498 random hard-sphere packing simulations representing 206 CPU days' worth of computational overhead. Simulations required nine input parameters with linear constraints and two discrete fidelities each with continuous fidelity parameters. The data was logged in a free-tier shared MongoDB Atlas database, producing two core tabular datasets: a failure probability dataset and a regression dataset. The failure probability dataset maps unique input parameter sets to the estimated probabilities that the simulation will fail. The regression dataset maps input parameter sets (including repeats) to particle packing fractions and computational runtimes for each of the two steps. These two datasets were used to create a surrogate model as close as possible to running the actual simulations by incorporating simulation failure and heteroskedastic noise. In the regression dataset, percentile ranks were calculated for each group of identical parameter sets to account for heteroskedastic noise, thereby ensuring reliable and accurate data. This differs from the conventional approach that imposes a-priori assumptions, such as Gaussian noise, by specifying mean and standard deviation. This technique can be extended to other benchmark datasets to bridge the gap between optimization benchmarks with low computational overhead and the complex optimization scenarios encountered in the real world.

Project description:BackgroundPhysicians need to inform asymptomatic individuals about personalized outcomes of statin therapy for primary prevention of cardiovascular disease (CVD). However, current prediction models focus on short-term outcomes and ignore the competing risk of death due to other causes. We aimed to predict the potential lifetime benefits with statin therapy, taking into account competing risks.Methods and findingsA microsimulation model based on 5-y follow-up data from the Rotterdam Study, a population-based cohort of individuals aged 55 y and older living in the Ommoord district of Rotterdam, the Netherlands, was used to estimate lifetime outcomes with and without statin therapy. The model was validated in-sample using 10-y follow-up data. We used baseline variables and model output to construct (1) a web-based calculator for gains in total and CVD-free life expectancy and (2) color charts for comparing these gains to the Systematic Coronary Risk Evaluation (SCORE) charts. In 2,428 participants (mean age 67.7 y, 35.5% men), statin therapy increased total life expectancy by 0.3 y (SD 0.2) and CVD-free life expectancy by 0.7 y (SD 0.4). Age, sex, smoking, blood pressure, hypertension, lipids, diabetes, glucose, body mass index, waist-to-hip ratio, and creatinine were included in the calculator. Gains in total and CVD-free life expectancy increased with blood pressure, unfavorable lipid levels, and body mass index after multivariable adjustment. Gains decreased considerably with advancing age, while SCORE 10-y CVD mortality risk increased with age. Twenty-five percent of participants with a low SCORE risk achieved equal or larger gains in CVD-free life expectancy than the median gain in participants with a high SCORE risk.ConclusionsWe developed tools to predict personalized increases in total and CVD-free life expectancy with statin therapy. The predicted gains we found are small. If the underlying model is validated in an independent cohort, the tools may be useful in discussing with patients their individual outcomes with statin therapy.

Dataset Information

Personalized statin treatment plan using counterfactual approach with multi-objective optimization over benefits and risks.

Background

Objectives

Methods

Results

Conclusion

Publications

Personalized statin treatment plan using counterfactual approach with multi-objective optimization over benefits and risks.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets